Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions

Authors: Jördis J Ott, Gretchen A Stevens, Steven T Wiersma

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

HBeAg presence in childbearing-age women is a major determinant of perinatal hepatitis B virus (HBV) transmission. The risk of developing chronic HBV infection and liver disease is highest at young age. Our aim was to assess perinatal HBV transmission risk by means of estimating age- and region-specific HBeAg prevalence.

Methods

Based on observed HBeAg seroprevalence data obtained from a systematic literature review, we modeled HBeAg prevalence using an empirical Bayesian hierarchical model. Age- and region-specific estimates were generated for 1990 and 2005.

Results

Globally, highest HBeAg prevalence of over 50 % was found in 0–9 years old girls. At reproductive age, HBeAg prevalence was 20-50 %. Prevalence was highest in young females in East Asia in 1990 (78 %), the infection was less common in Sub-Saharan and North Africa. Regional differences in prevalence were smaller in 2005. There was an overall decrease in HBeAg between 1990 and 2005, which was strongest among girls in Oceania (23.3 % decline), South and South-East Asia (14 % decline). However, in these regions, prevalence remained high at 67 % among young females in 2005. Smaller decreases were observed in women at reproductive age, at which 24-32 % of all HBsAg-positive women were HBeAg-positive in 2005, with lowest prevalence in Southern Sub-Saharan Africa and highest prevalence in Oceania and South-East Asia.

Conclusions

HBeAg estimates are crucial for understanding the epidemiology of HBV and for prioritizing implementation of WHO`s prevention recommendations for all infants to receive the first dose of hepatitis B vaccine within 24 hours of birth. Results will have importance as access to treatment for chronic HBV infection is expanded.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization: Hepatitis B vaccines. Weekly epidemiological record 2009. 2009, 20-405. World Health Organization: Hepatitis B vaccines. Weekly epidemiological record 2009. 2009, 20-405.
2.
go back to reference Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC): A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006, 55 (RR-16): 1-33.PubMed Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC): A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006, 55 (RR-16): 1-33.PubMed
3.
go back to reference Ni YH: Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2011, 46: 1-8.CrossRefPubMed Ni YH: Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2011, 46: 1-8.CrossRefPubMed
4.
go back to reference Beasley RP: Rocks along the road to the control of HBV and HCC. Ann Epidemiol. 2009, 19: 231-234. 10.1016/j.annepidem.2009.01.017.CrossRefPubMed Beasley RP: Rocks along the road to the control of HBV and HCC. Ann Epidemiol. 2009, 19: 231-234. 10.1016/j.annepidem.2009.01.017.CrossRefPubMed
5.
go back to reference Dwivedi M, Misra SP, Misra V, Pandey A, Pant S, Singh R, Verma M: Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission. Indian J Gastroenterol. 2011, 30: 66-71. 10.1007/s12664-011-0083-y.CrossRefPubMed Dwivedi M, Misra SP, Misra V, Pandey A, Pant S, Singh R, Verma M: Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission. Indian J Gastroenterol. 2011, 30: 66-71. 10.1007/s12664-011-0083-y.CrossRefPubMed
6.
go back to reference Edmunds WJ, Medley GF, Nokes DJ, O`Callaghan CJ, Whittle HC, Hall AJ: Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996, 117: 313-325. 10.1017/S0950268800001497.CrossRefPubMedPubMedCentral Edmunds WJ, Medley GF, Nokes DJ, O`Callaghan CJ, Whittle HC, Hall AJ: Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996, 117: 313-325. 10.1017/S0950268800001497.CrossRefPubMedPubMedCentral
7.
go back to reference Knorr B, Maul H, Schnitzler P: Prevalence of hepatitis B virus infection among women at reproductive age at a German university hospital. J Clin Virology. 2008, 42: 422-4. 10.1016/j.jcv.2008.03.009.CrossRef Knorr B, Maul H, Schnitzler P: Prevalence of hepatitis B virus infection among women at reproductive age at a German university hospital. J Clin Virology. 2008, 42: 422-4. 10.1016/j.jcv.2008.03.009.CrossRef
8.
go back to reference Shao ZJ, Zhang L, Xu JQ, Xu DZ, Men K, Zhang JX, Cui HC, Yan YP: Mother-to-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol. 2011, 83: 791-5. 10.1002/jmv.22043.CrossRefPubMed Shao ZJ, Zhang L, Xu JQ, Xu DZ, Men K, Zhang JX, Cui HC, Yan YP: Mother-to-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol. 2011, 83: 791-5. 10.1002/jmv.22043.CrossRefPubMed
9.
go back to reference Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH: Hepatitis B surface antigenemia at birth: a long-term follow up study. J Pediatr. 1998, 133: 374-7. 10.1016/S0022-3476(98)70272-0.CrossRefPubMed Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH: Hepatitis B surface antigenemia at birth: a long-term follow up study. J Pediatr. 1998, 133: 374-7. 10.1016/S0022-3476(98)70272-0.CrossRefPubMed
10.
go back to reference Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, Maley MW, Ayres A, Locarnini SA, Levy MT: Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009, 190: 489-92.PubMed Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, Maley MW, Ayres A, Locarnini SA, Levy MT: Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009, 190: 489-92.PubMed
11.
go back to reference Shikata T, Karasawa T, Abe K, et al: Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis. 1977, 136: 571-6. 10.1093/infdis/136.4.571.CrossRefPubMed Shikata T, Karasawa T, Abe K, et al: Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis. 1977, 136: 571-6. 10.1093/infdis/136.4.571.CrossRefPubMed
12.
go back to reference Alter HJ, Seeff LB, Kaplan PM, et al: Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med. 1976, 295: 909-13. 10.1056/NEJM197610212951701.CrossRefPubMed Alter HJ, Seeff LB, Kaplan PM, et al: Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med. 1976, 295: 909-13. 10.1056/NEJM197610212951701.CrossRefPubMed
13.
go back to reference Beasley RP, Trepo C, Stevens CE, Szmuness W: The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977, 105: 94-8.PubMed Beasley RP, Trepo C, Stevens CE, Szmuness W: The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977, 105: 94-8.PubMed
14.
go back to reference Chang MH: Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007, 12: 160-167. 10.1016/j.siny.2007.01.013.CrossRefPubMed Chang MH: Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007, 12: 160-167. 10.1016/j.siny.2007.01.013.CrossRefPubMed
15.
go back to reference McMahon BJ, Alward WL, Hall DB, et al: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985, 151: 599-603. 10.1093/infdis/151.4.599.CrossRefPubMed McMahon BJ, Alward WL, Hall DB, et al: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985, 151: 599-603. 10.1093/infdis/151.4.599.CrossRefPubMed
16.
go back to reference Chang MH, Sung JL, Lee CY, et al: Factors affecting clearance of hepatitis Be antigen in hepatitis B surface antigen carrier children. J Pediatr. 1989, 115: 385-390. 10.1016/S0022-3476(89)80836-4.CrossRefPubMed Chang MH, Sung JL, Lee CY, et al: Factors affecting clearance of hepatitis Be antigen in hepatitis B surface antigen carrier children. J Pediatr. 1989, 115: 385-390. 10.1016/S0022-3476(89)80836-4.CrossRefPubMed
17.
go back to reference Hadziyannis SJ: Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol. 2011, 55: 183-191. 10.1016/j.jhep.2010.12.030.CrossRefPubMed Hadziyannis SJ: Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol. 2011, 55: 183-191. 10.1016/j.jhep.2010.12.030.CrossRefPubMed
18.
go back to reference Grosheide PM, Wladimiroff JW, Heijtink RA, Mazel JA, Christiaens GCML, Nuijten ASM, Schaldm SW, the Dutch Study Group on Prevention of Neonatal hepatitis: Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. BMJ. 1995, 311: 99-1197. 10.1136/bmj.311.6997.99.CrossRef Grosheide PM, Wladimiroff JW, Heijtink RA, Mazel JA, Christiaens GCML, Nuijten ASM, Schaldm SW, the Dutch Study Group on Prevention of Neonatal hepatitis: Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. BMJ. 1995, 311: 99-1197. 10.1136/bmj.311.6997.99.CrossRef
19.
go back to reference Op de Coul EL, Hahne S, van Weert YW, Oomen P, Smit C, van der Ploeg KP, Notermans DW, Boer K, Van der Sande MA: Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective. BMC Infect Dis. 2011, 11: 185-10.1186/1471-2334-11-185.CrossRefPubMedPubMedCentral Op de Coul EL, Hahne S, van Weert YW, Oomen P, Smit C, van der Ploeg KP, Notermans DW, Boer K, Van der Sande MA: Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective. BMC Infect Dis. 2011, 11: 185-10.1186/1471-2334-11-185.CrossRefPubMedPubMedCentral
20.
go back to reference Global Burden of Diseases, Injuries and Risk Factors Study 2005: Global Burden of Diseases, Injuries and Risk Factors Study operations manual (final draft, January 2009). 2009, Available from http://www.globalburden.org Global Burden of Diseases, Injuries and Risk Factors Study 2005: Global Burden of Diseases, Injuries and Risk Factors Study operations manual (final draft, January 2009). 2009, Available from http://​www.​globalburden.​org
21.
go back to reference Ott JJ, Stevens GA, Groeger J, Wiersma ST: Global epidemiology of hepatitis B virus infection: New estimates of age-specific HbsAg seroprevalence and endemicity. Accepted for publication in Vaccine, in press Ott JJ, Stevens GA, Groeger J, Wiersma ST: Global epidemiology of hepatitis B virus infection: New estimates of age-specific HbsAg seroprevalence and endemicity. Accepted for publication in Vaccine, in press
23.
go back to reference Beckers K, Schaad UB, Heininger U: Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. Eur J Pediatr. 2004, 163: 654-657.PubMed Beckers K, Schaad UB, Heininger U: Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. Eur J Pediatr. 2004, 163: 654-657.PubMed
24.
go back to reference Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS: The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995, 22: 1387-1392.PubMed Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS: The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 1995, 22: 1387-1392.PubMed
25.
go back to reference Oshitani H, Kasolo FC, Mpabalwani M, Mizuta K, Luo NP, Suzuki H, Numazaki Y: Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg. 1996, 90: 235-236. 10.1016/S0035-9203(96)90227-8.CrossRefPubMed Oshitani H, Kasolo FC, Mpabalwani M, Mizuta K, Luo NP, Suzuki H, Numazaki Y: Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg. 1996, 90: 235-236. 10.1016/S0035-9203(96)90227-8.CrossRefPubMed
26.
go back to reference Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al: Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology. 2003, 37: 19-26. 10.1053/jhep.2003.50036.CrossRefPubMed Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al: Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology. 2003, 37: 19-26. 10.1053/jhep.2003.50036.CrossRefPubMed
27.
go back to reference Chu CJ, Hussain M, Lok AS: Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002, 122: 1756-1762. 10.1053/gast.2002.33588.CrossRefPubMed Chu CJ, Hussain M, Lok AS: Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002, 122: 1756-1762. 10.1053/gast.2002.33588.CrossRefPubMed
28.
go back to reference Chu CM, Liaw YF: Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005, 43: 411-417. 10.1016/j.jhep.2005.03.018.CrossRefPubMed Chu CM, Liaw YF: Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005, 43: 411-417. 10.1016/j.jhep.2005.03.018.CrossRefPubMed
29.
go back to reference Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al: Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007, 133: 1452-1457. 10.1053/j.gastro.2007.08.010.CrossRefPubMed Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al: Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007, 133: 1452-1457. 10.1053/j.gastro.2007.08.010.CrossRefPubMed
30.
go back to reference Olinger CM, Venard V, Njayou M, Oyefolu AO, Maïga I, Kemp AJ, Omilabu SA, le Faou A, Muller CP: Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations. J Gen Virol. 2006, 87: 1163-1173. 10.1099/vir.0.81614-0.CrossRefPubMed Olinger CM, Venard V, Njayou M, Oyefolu AO, Maïga I, Kemp AJ, Omilabu SA, le Faou A, Muller CP: Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations. J Gen Virol. 2006, 87: 1163-1173. 10.1099/vir.0.81614-0.CrossRefPubMed
31.
go back to reference Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya SK, Gish RG, Kramvis A, Kew MC, Yoshihara N, Shrestha SM, Khan M, Miyakawa Y, Mizokami M: A case–control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology. 2004, 40: 747-755. 10.1002/hep.20365.CrossRefPubMed Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya SK, Gish RG, Kramvis A, Kew MC, Yoshihara N, Shrestha SM, Khan M, Miyakawa Y, Mizokami M: A case–control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology. 2004, 40: 747-755. 10.1002/hep.20365.CrossRefPubMed
32.
go back to reference Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, Oh JK, Park S, Kim YJ, Shin HR, Yoo KY, Park SK: Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011, 128: 176-184. 10.1002/ijc.25321.CrossRefPubMed Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, Oh JK, Park S, Kim YJ, Shin HR, Yoo KY, Park SK: Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011, 128: 176-184. 10.1002/ijc.25321.CrossRefPubMed
33.
go back to reference Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ: Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002, 347: 168-174. 10.1056/NEJMoa013215.CrossRefPubMed Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ: Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002, 347: 168-174. 10.1056/NEJMoa013215.CrossRefPubMed
34.
go back to reference Wiersma ST, McMahon B, Pawlotsky JM, et al: Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 2010, [Epub ahead of print] Wiersma ST, McMahon B, Pawlotsky JM, et al: Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 2010, [Epub ahead of print]
35.
go back to reference Guidozzi F, Schoub BD, Johnson S, Song E: Should pregnant urban south African women be screened for hepatitis B?. S Afr Med J. 1993, 83: 103-5.PubMed Guidozzi F, Schoub BD, Johnson S, Song E: Should pregnant urban south African women be screened for hepatitis B?. S Afr Med J. 1993, 83: 103-5.PubMed
36.
go back to reference Madzime S, Adem M, Mahomed K, Woelk GB, Mudzamiri S, Williams MA: Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare Zimbabwe, 1996 to 1997. Cent Afr J Med. 1999, 45: 195-8.PubMed Madzime S, Adem M, Mahomed K, Woelk GB, Mudzamiri S, Williams MA: Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare Zimbabwe, 1996 to 1997. Cent Afr J Med. 1999, 45: 195-8.PubMed
37.
go back to reference Sriprakash I, Anil TP: Routine prenatal screening of Indian women for HBsAg: benefits derived versus cost. Trop Doct. 1997, 27: 176-7.PubMed Sriprakash I, Anil TP: Routine prenatal screening of Indian women for HBsAg: benefits derived versus cost. Trop Doct. 1997, 27: 176-7.PubMed
Metadata
Title
The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions
Authors
Jördis J Ott
Gretchen A Stevens
Steven T Wiersma
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-131

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.